Specificity of activated human Protein C

Stuart R. STONE and Jan HOFSTEENGE
Friedrich Miescher Institut, P.O. Box 2543, CH-4002 Basel, Switzerland

(Received 6 March 1985/9 May 1985; accepted 14 May 1985)

Peptide p-nitroanilide substrates and peptidylchloromethane inhibitors were used to examine the specificity of activated human Protein C. Substrates with arginine in the P₁ position had the highest activity. The best substrates and inhibitors, as judged by the second-order rate constant for their interaction with the enzyme, had an apolar residue in the P₂ position. In contrast with thrombin [Kettner & Shaw (1981) Methods Enzymol. 80, 826–842], activated Protein C was able to accommodate large hydrophobic residues such as phenylalanine and leucine in the P₂ position. In the P₃ position, the enzyme preferred an apolar d-amino acid residue. The results of the present study have also indicated a suitable substrate and inhibitor to be used in the assay of functional protein C and of thrombomodulin.

Protein C appears to play an important role in the regulation of blood coagulation (Esmon, 1983). Activated Protein C inhibits coagulation by inactivating Factors V and VIII (Kisiel et al., 1977; Vehar & Davie, 1980; Malar et al., 1982). The importance of Protein C is indicated by the fact that low concentrations of Protein C are associated with recurrent familial thrombosis (Griffin et al., 1981; Bertina et al., 1982).

Protein C circulates in plasma as a two-chain zymogen (Kisiel, 1979) that is slowly activated by thrombin alone, but is much more rapidly activated by thrombin in the presence of an endothelial-cell cofactor called thrombomodulin (Esmon et al., 1982; Salem et al., 1984). Additionally, Factor Va is a less efficient cofactor in the activation reaction (Salem et al., 1983a,b).

Despite the proposed importance for Protein C in the regulation of coagulation, very little is known about the substrate specificity of activated human Protein C with respect to its natural or synthetic substrates. In the current study, we have determined the kinetic parameters of commercially available peptide p-nitroanilide substrates with human activated Protein C. These experiments yielded information on substrate specificity of the enzyme. The specificity of the enzyme was further examined by determining the kinetics of its inactivation by a number of peptidylchloromethane inhibitors.

Experimental

Materials

Peptide p-nitroanilide substrates with the nomenclature ‘Chromozym’ were obtained from Boehringer Biochemicals, Tutzing, Germany, and those with the ‘S-*****’ nomenclature were from AB Kabi, Molndal, Sweden. Peptidylchloromethanes were generously provided by Dr. E. Shaw. Snake venom from Oxyurus scutellatus was from Sigma Chemical Co., St. Louis, MO, U.S.A., and frozen rabbit lungs were supplied by Pel-Freez, Rogers, AR, U.S.A. Fresh or fresh-frozen human plasma was provided by the Blutspendezentrum, Basel, Switzerland. All other chemicals were of the highest purity available commercially.

Preparation of activated Protein C

Protein C and prothrombin were purified from human plasma by the methods of Suzuki et al. (1983) and Miletich et al. (1981) respectively. Thrombomodulin was isolated from frozen rabbit lungs (Esmon et al., 1982). Prothrombin was activated to thrombin with the venom of O. scutellatus (Owen & Jackson, 1973) and purified on SP- (sulphopropyl-)Sephadex (Lundblad, 1971). Protein C was activated by human thrombin in the presence of rabbit thrombomodulin (Salem et al., 1984) and purified by the method of Kisiel & Davie (1981).

Abbreviations used: (in sequences): <Glu, 5-oxopyrrolidine-2-carboxylic acid; Pip, piperidyl; APro, 3,4-dehydroproline; Suc, 3-carboxypropionyl; Tos, toluene-p-sulphonyl; Bz, benzoyl; Cbz, benzoxycarbonyl; Nan, p-nitroanilide.

Vol. 230
Assay of activated Protein C

The rate of peptide p-nitroanilide hydrolysis was determined by using a Shimadzu UV240 spectrophotometer to measure the increase in absorbance at 405 nm that resulted from the release of p-nitroaniline. The reactions were performed in polystyrene cuvettes at 37°C in 50 mm Tris/HCl buffer, pH 7.8, containing 0.1 m NaCl, 0.1% poly(ethylene glycol) (Mw 6000) and 1.0 mm CaCl2. Activated Protein C was present in the assays at concentrations of 2–200 nM. Under the assay conditions, activated Protein C was stable for at least 10 min, as determined by the progress-curve method of Selwyn (1965). An absorption coefficient of 9920 M⁻¹ cm⁻¹ at 405 nm for p-nitroaniline was used in the calculation of the amount of product formed (Lottenberg & Jackson, 1983). The concentration of the peptide p-nitroanilide substrates was determined spectrophotometrically at 342 nm by using an absorption coefficient of 8270 M⁻¹ cm⁻¹ (Lottenberg & Jackson, 1983).

In experiments that examined the activity of activated Protein C with various peptide p-nitroanilide substrates, the substrate was varied over a 9-fold range. Five different initial substrate concentrations were used, and each point was measured in duplicate.

In experiments that examined the inhibitory effects of peptidylchloromethanes, the substrate S-2238 was present at a concentration of 400 μM. The inhibitor was added immediately before the assay was started by the addition of the enzyme. In the absence of inhibitors, the rate of product formation was linear up to a product concentration of greater than 10 μM, which represents 2.5% substrate utilization. In the presence of inhibitor, the reaction was allowed to proceed until the amount of product formed was 10 μM or until the activity of the enzyme was negligible. Ten data points were taken for analysis from each curve at approximately equal increments of product formation.

Determination of the concentration of activated Protein C

The concentration of activated Protein C was determined by active-site titration with methylumbelliferyl p-guanidinobenzoate by the method of Jameson et al. (1973). This method assumes that the concentration of titrant is sufficient to saturate the enzyme; and, under these conditions, the amplitude of the initial burst is equal to the concentration of the active enzyme. Activated Protein C was not, however, saturated with the concentrations of the titrant routinely used (10 μM). Therefore the amplitude of the initial burst that occurred before a steady-state turnover was measured at a number of titrant concentrations and extrapolation was made to infinite concentration. The concentration of activated Protein C was taken to be equal to the calculated amplitude of the initial burst at infinite titrant concentration. The concentration of activated Protein C calculated in this manner agreed well with that based on the absorbance of the enzyme solution at 280 nm (Kisiel, 1979).

Data analysis

For initial-velocity experiments in which the velocity was hyperbolically dependent on the substrate concentration, the data were fitted to the Michaelis–Menten equation by weighted non-linear regression (Duggleby, 1981). The weighting used assumed proportional errors (Cornish-Bowden, 1977), and, in addition, bisquare weighting was included to mitigate the effect of outliers as recommended by Mosteller & Tukey (1977). For some substrates, velocity was directly proportional to substrate concentration, and for these substrates the second-order rate constant V/Km was determined by weighted linear regression.

The irreversible inhibition of an enzyme in the presence of a substrate can be represented by the following scheme:

\[
E + S \xrightarrow{K_o} ES \xrightarrow{k_o} E + P
\]

\[
I \xrightarrow{k_i} EI
\]

where EI* is the irreversibly inactivated enzyme. If it is assumed that substrate and inhibitor binding are in rapid equilibrium and that the substrate concentration does not change significantly during the course of the assay, the concentration of product, [P], at time t after the initiation of the reaction will be given by eqn. (1) (Walker & Elmore, 1984; Tian & Tsou, 1982):

\[
[P] = \frac{v_i}{k_{app}} \left[ 1 - \exp\left(-k_{app}t\right) \right] + d \tag{1}
\]

where

\[
v_i = \frac{v[S]}{[S] + K_m(1 + [I]/K_i)} \tag{2}
\]

\[
k_{app} = \frac{k_i[I]}{[I] + K_i(1 + [S]/K_m)} \tag{3}
\]

and d is a displacement term to account for the fact that at \( t = 0 \) the absorbance is not accurately known. Progress curves for the inactivation of activated Protein C by peptidylchloromethanes were fitted by non-linear regression to eqn. (1).

1985
Progress curves were obtained with at least five different concentrations of inhibitor. The values of $k_{\text{app}}$, obtained from these analyses were weighted according to the squared inverse of their standard errors and fitted to eqn. (3). This procedure yielded values for $K_i$ and $K_i(1 + [S]/K_m)$. The value of $K_m$ obtained from initial-velocity studies was used to calculate the value of $K_i$. The variation of $v_i$ with $[I]$ could also be used to estimate $K_i$ (eqn. 2). As discussed by Duggleby et al. (1982), however, $k_{\text{app}}$ is less subject to systematic error, and consequently eqn. (3) was used for the estimation of $K_i$. For one inhibitor, $k_{\text{app}}$ was directly proportional to $[I]$, and a value for the second-order rate constant $k_i/K_i$ was obtained by weighted linear regression.

**Results and discussion**

**Substrate specificity of human activated Protein C**

The values for the maximum velocity ($V$) and Michaelis constant ($K_m$) obtained with a number of peptide $p$-nitroanilide substrates are given in Table 1. The second-order rate constant $V/K_m$ is the simplest single parameter for assessing the substrate specificity of an enzyme (Fersht, 1977), and values of this parameter for thrombin are given for comparison in Table 1. With activated Protein C, values obtained for $V/K_m$ varied by four orders of magnitude, from $3.3 \times 10^3 \text{M}^{-1} \cdot \text{s}^{-1}$ for $\text{d-Ille-Pro-Arg-Nan}$ to less than $10 \text{M}^{-1} \cdot \text{s}^{-1}$ for $<\text{Glu-Pro-Val-Nan}$ and $\text{MeOSuc-Arg-Pro-Lys-Nan}$. The preference of the enzyme for an arginine residue in the $P_1$ position is clear from the data of Table 1. Under the assay conditions used, $<\text{Glu-Pro-Val-Nan}$ was not cleaved and substrates with lysine in the $P_1$ position were in general cleaved poorly. There were two substrate pairs that differed only in their $P_1$ residue: $\text{Tos-Gly-Pro-Arg/Lys-Nan}$ (Chromozym TH and PL) and $\text{d-Val-Leu-Arg/Lys-Nan}$ (S-2266 and S-2251). For these two substrate pairs, the value of $V/K_m$ for the arginine derivatives were 17-fold and 316-fold higher respectively. It may be noted that the substitution of lysine for arginine in $\text{Tos-Gly-Pro-Arg-Nan}$ caused a decrease in $K_m$ as well as a decrease in $V$. Activated Protein C appears to prefer a bulky non-polar amino acid residue in the $P_2$ position. For thrombin, the best $p$-nitroanilide substrates have a proline in this position (Lottenberg et al., 1981, 1983). Such substrates were also among the best for activated Protein C, but it was also able to accommodate much larger residues, such as phenylalanine and leucine, in the $P_2$ position (Table 1). Cho et al. (1984) have also shown that phenylalanine is preferred to glycine in the $P_2$ position of tripeptide $p$-nitroanilide substrates by activated human Protein C. In the same study, phenylalanine was a preferred residue in the $P_2$ position of dipeptide thioester substrates. In its preference for phenylalanine in the $P_2$ position, activated

<table>
<thead>
<tr>
<th>$p$-Nitroanilide derivative of peptide</th>
<th>Activated human Protein C</th>
<th>Human thrombin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$V$ ($\text{s}^{-1}$)</td>
<td>$K_m$ (M)</td>
</tr>
<tr>
<td>Tos-Gly-Pro-Arg (Chromozym TH)</td>
<td>87 ± 7</td>
<td>762 ± 95</td>
</tr>
<tr>
<td>d-Phe-Pip-Arg (S-2238)</td>
<td>53 ± 1</td>
<td>373 ± 37</td>
</tr>
<tr>
<td>d-Ile-Pro-Arg (S-2288)</td>
<td>200 ± 8</td>
<td>606 ± 36</td>
</tr>
<tr>
<td>d-Pro-Phe-Arg (S-2302)</td>
<td>31 ± 1</td>
<td>505 ± 37</td>
</tr>
<tr>
<td>d-Val-Leu-Arg (S-2266)</td>
<td>35 ± 1</td>
<td>345 ± 18</td>
</tr>
<tr>
<td>d-Val-cyclohexylAla-Arg (Chromozym GK)</td>
<td>1.9 ± 0.1</td>
<td>259 ± 28</td>
</tr>
<tr>
<td>Tos-Gly-Pro-Lys (Chromozym PL)</td>
<td>0.81 ± 0.03</td>
<td>116 ± 11</td>
</tr>
<tr>
<td>Cbz-VaI-Gly-Arg (Chromozym TRY)</td>
<td>0.38 ± 0.04</td>
<td>528 ± 90</td>
</tr>
<tr>
<td>&lt;Glu-Gly-Argl (S-2244)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cbz-Ile-Glu-Gly-Argl (S-2222)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>d-Val-Leu-Lysl (S-2251)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bz-Pro-Phe-Argl (Chromozym PK)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>&lt;Glu-Pro-Val§ (S-2484)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>MeOSuc-Arg-Pro-Lys§ (S-2586)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

* Lottenberg et al. (1981).
† AB Kabi, manufacturer's literature.
‡ Value for bovine thrombin (Lottenberg et al., 1983).
§ No activity was observed with 400 M substrate and 200 M enzyme; $V/K_m$ can be assumed to be less than $10^{-1} \cdot \text{s}^{-1}$.
|| The $K_m$ was greater than 2000 M and the velocity appeared to be directly proportional to substrate concentration.
Protein C is similar to kallikreins (Lottenberg et al., 1981). Thrombin, in contrast, cleaves substrates with phenylalanine in the P2 position relatively poorly (Table 1).

With activated human Protein C the best substrates yielded a $V/K_m$ value of about $10^5 M^{-1} \cdot s^{-1}$, whereas with thrombin the best values were in excess of $10^3 M^{-1} \cdot s^{-1}$ (Table 1). Thus it should be possible to obtain better synthetic substrates for activated Protein C. Any improvement in the value of $V/K_m$ for substrates of activated Protein C is likely to be achieved by decreasing the value of $K_m$ rather than by increasing $V$. In comparison with the best substrates for thrombin, the best substrates for activated Protein C yielded similar values for $V$, but the values for $K_m$ were two orders of magnitude larger (Lottenberg et al., 1981).

Protein C circulates in plasma as a zymogen (Esmon, 1983), and in order to measure the concentration of functional Protein C it must first be activated by thrombin (Sala et al., 1984; Comp et al., 1984). Thrombin must subsequently be inactivated before activated Protein C is measured. The assay of the endothelial-cell cofactor thrombomodulin involves the same procedure (Esmon et al., 1982; Salem et al., 1984). An ideal substrate for activated Protein C in these assays would have a much higher activity with activated Protein C than with thrombin at concentrations of both that are present in the assay. With such a substrate, incomplete inactivation of thrombin would not produce significant error. If the difference in activities were large enough, the thrombin-inactivation step could be omitted in the assay of functional Protein C. From the data presented in Table 1, D-Val-Leu-Arg-Nan (S-2266) would appear to be the best available substrate for this purpose. Protein C and thrombomodulin assays usually contain thrombin at a concentration of about 1% of that of Protein C. At these concentrations, hydrolysis of S-2266 by thrombin is negligible in comparison with that of activated Protein C at all but the lowest extents of Protein C conversion. In fact, if S-2266 is used in the Protein C assay, only a slight increase in background absorbance is observed if the thrombin inactivation step is omitted.

**Inactivation of human activated Protein C by peptidylchloromethanes**

Twenty peptidylchloromethanes were tested as inhibitors by using a continuous assay. The data from a typical experiment are shown in Fig. 1, and the results obtained for all the inhibitors tested are given in Table 2. The inhibitors tested could be divided into three major classes: 1, inhibitors with a proline in the P2 position, which had been designed as inhibitors of thrombin; 2, inhibitors with a phenylalanine in the P2 position, which had been designed as inhibitors of kallikreins; 3, inhibitors with glycine in the P2 position, which had been designed as inhibitors of Factor Xa. In addition, several other compounds were tested. Inhibitors with glycine in the P2 position failed to inactivate the enzyme. With the slightly larger residue alanine in the P2 position inhibition was observed (Table 2). Thrombin inhibitors with a proline in the P2 position were among the best inhibitors of activated Protein C. Similar results have been obtained by Lijen et al. (1984). Unlike thrombin, however, activated Protein C seems to be able to accommodate the more bulky phenylalanine residue in the P2 position. Thus, for activated Protein C, D-Phe-Pro-Arg-CH2Cl and D-Phe-Phe-Arg-CH2Cl yielded the same apparent second-order rate constant for the inactivation ($k_i/K_i = 3.7 \times 10^3 M^{-1} \cdot s^{-1}$). In contrast, for bovine thrombin D-Phe-Pro-Arg-CH2Cl yielded a rate constant 1500-fold larger (Kettner & Shaw, 1981). A compound with leucine in the P2 position is also a satisfactory inhibitor of activated Protein C (Table 2). The importance of a D-amino acid in the P3 position is seen by comparing the values of $k_i/K_i$,
Table 2. Parameters for the inactivation of human activated Protein C by peptidylchloromethanes

<table>
<thead>
<tr>
<th>Peptidylchloromethane inhibitor</th>
<th>$K_i$ (μM)</th>
<th>$10^{-2} \times k_i$ (s⁻¹)</th>
<th>$10^{-2} \times k_i/K_i$ (m⁻¹s⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-Phe-Pro-Arg-CH₂Cl</td>
<td>8.4 ± 1.0</td>
<td>3.08 ± 0.27</td>
<td>37</td>
</tr>
<tr>
<td>D-Tyr-Pro-Arg-CH₂Cl</td>
<td>5.8 ± 1.6</td>
<td>2.10 ± 0.40</td>
<td>37</td>
</tr>
<tr>
<td>D-Phe·APrO·Arg-CH₂Cl</td>
<td>7.5 ± 3.9</td>
<td>0.92 ± 0.25</td>
<td>12</td>
</tr>
<tr>
<td>I₁-D-Phe·Pro-Arg-CH₂Cl</td>
<td>1.5 ± 0.1</td>
<td>0.57 ± 0.01</td>
<td>38</td>
</tr>
<tr>
<td>p-NH₂-D-Phe·Pro-Arg-CH₂Cl</td>
<td>5.7 ± 1.5</td>
<td>1.93 ± 0.37</td>
<td>33</td>
</tr>
<tr>
<td>ε-Bz-D-Lys·Pro-Arg-CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bz·Ala·d-Phe·Pro-Arg-CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Ile·Pro·Arg·CH₂Cl</td>
<td>210 ± 20</td>
<td>2.82 ± 0.18</td>
<td>0.38</td>
</tr>
<tr>
<td>D-Phe·Phe·Arg·CH₂Cl</td>
<td>4.9 ± 0.4</td>
<td>1.18 ± 0.07</td>
<td>37</td>
</tr>
<tr>
<td>Phe·Phe·Arg·CH₂Cl</td>
<td>87 ± 6</td>
<td>1.03 ± 0.03</td>
<td>1.18</td>
</tr>
<tr>
<td>Tyr·Phe·Arg·CH₂Cl</td>
<td>127 ± 30</td>
<td>1.23 ± 0.17</td>
<td>0.97</td>
</tr>
<tr>
<td>Ala·Phe·Arg·CH₂Cl</td>
<td>135 ± 48</td>
<td>1.55 ± 0.40</td>
<td>1.15</td>
</tr>
<tr>
<td>Pro·Phe·Arg·CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Ac·Phe·Phe·Arg·CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Ile·Glu·Gly·Arg·CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Ac·Gly·Gly·Arg·CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Glu·Gly·Arg·CH₂Cl</td>
<td>—</td>
<td>—</td>
<td>&lt;0.2†</td>
</tr>
<tr>
<td>Val·Val·Arg·CH₂Cl</td>
<td>135 ± 35</td>
<td>1.60 ± 0.28</td>
<td>1.28</td>
</tr>
<tr>
<td>Phe·Ala·Arg·CH₂Cl</td>
<td>157 ± 33</td>
<td>0.97 ± 0.10</td>
<td>0.62</td>
</tr>
<tr>
<td>Ile·Leu·Arg·CH₂Cl</td>
<td>105 ± 55</td>
<td>2.28 ± 0.92</td>
<td>2.18</td>
</tr>
</tbody>
</table>

* The value of $k_{app}$ varied linearly with inhibitor concentration.
† No inhibition was observed with a concentration of 100μM inhibitor within a period of 5min, and therefore the second-order rate constant $k_i/k_i$ was assumed to be less than $20\text{m}^{-1}\text{s}^{-1}$.

for the two isomers of Phe·Phe·Arg·CH₂Cl; the D-isomer is 31-fold more active than the L-isomer, and the increase in the second-order rate constant with the D-isomer is due entirely to a decrease in the binding constant (Table 2). The best substrates for activated Protein C also have D-amino acid residues in the P₃ position (Table 1). Similar observations have been made with thrombin (Kettner & Shaw, 1981; Lottenberg et al., 1983).

The compound Bz·Ala·d-Phe·Pro·Arg·CH₂Cl is interesting from the point of view of the assay of Protein C and thrombomodulin. This compound is a very effective inhibitor of human thrombin, yielding a value of $3.8 \times 10^5 \text{m}^{-1}\text{s}^{-1}$ for $k_i/K_i$ (Walker et al., 1985). In contrast, the value of $k_i/K_i$ for this compound with human activated Protein C was less than $20\text{m}^{-1}\text{s}^{-1}$. As discussed above, the assay for Protein C and thrombomodulin requires that thrombin be inactivated after the first stage. Bz·Ala·d-Phe·Pro·Arg·CH₂Cl would be a most suitable compound for this purpose. At a concentration of 10μM thrombin would be inactivated within seconds, whereas the half-life for inactivation of activated Protein C would be greater than 100min.

We thank Dr. Elliot Shaw for providing the peptidylchloromethane inhibitors and for his careful reading of the manuscript, and Dr. Brian Walker and Dr. Brian Hemmings for their critical reading of the manuscript. The excellent technical assistance of Ms. Monique Pedroca is also gratefully acknowledged.

References
